Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.71 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503892 | 0.89 | OPRM1 (0.73) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL8437630 | 0.86 | OPRM1 (0.69) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL5848377 | 0.86 | OPRD1 (0.54) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL17520399 | 0.86 | OPRM1 (0.69) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL5330651 | 0.84 | CYP2D6 (0.61) | OPRM1OPRD1OPRK1KCNA3 | |
| SCHEMBL11712071 | 0.83 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL6504241 | 0.83 | OPRM1 (0.65) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL8324812 | 0.81 | OPRM1 (0.63) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL18068774 | 0.81 | OPRM1 (0.62) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL6643987 | 0.81 | OPRM1 (0.53) | OPRM1OPRD1OPRK1ADRA1AKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105493-A1 | HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-7329658-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CARPINO PHILIP A | 2007-09-13 | — | — | US | disclosed |
| US-7232823-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | OPRM1 6/4885OPRD1 9/4885OPRK1 5/4885 |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR2, CNR1, GPR18 | OPRM1 12/4885OPRD1 31/4885OPRK1 5/4885 |
| US-20110105493-A1 | HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | OPRM1 364/4885OPRD1 230/4885OPRK1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.